FUS instruments is a manufacturer of preclinical foucsed ultrasound systems for research. We specialize in systems for brain research. We sell stereotactic and MRI-guided FUS systems as well as transducer and other accessories for focused ultrasound research.
(Nanowerk News) Advanced technologies enable the controlled release of medicine to specific cells in the body. Scientists argue these same technologies must be applied to agriculture if growers are to meet increasing global food demands.
In a new Nature Nanotechnology journal review paper (“Towards realizing nano-enabled precision delivery in plants”), scientists from UC Riverside and Carnegie Mellon University highlight some of the best-known strategies for improving agriculture with nanotechnology.
GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK). The study included 42 patients suffering from mismatch repair deficient (dMMR) locally advanced rectal cancer, a type of bowel cancer.
Used as a first-line treatment and an alternative to chemotherapy and surgery, Jemperli cured cancer in all patients, showing “an unprecedented 100% clinical complete response rate.” Tests that followed showed no evidence of remaining tumors. Moreover, the first 24 of the 42 patients were observed after an average time of 26.3 months, and they showed no signs of cancer resurfacing.
GSK will test the drug in additional studies involving certain types of colorectal cancers.
Seedless blackberry, CRISPR.
US company introduces the world’s first seedless blackberry, revolutionizing fruit consumption and market dynamics.
Researchers from the University of Colorado Anschutz Medical Campus have established a new framework for understanding how classic antidepressants work in treating major depressive disorder (MDD), reemphasizing their importance and aiming to reframe clinical conversation around their role in treatment.
In what researchers have called an “unprecedented” response, a new drug that treats locally advanced rectal cancer has shown to have completely eradicated tumors in all 42 patients who took part in the Phase II trial.
The drug, Jemperli (dostarlimab-gxly), had earlier shown great potential for eliminating mismatch repair deficient (dMMR) cancers, which make up 5–10% of colorectal cancers. Following the Phase II trial, the first 24 patients assessed showed a “sustained complete clinical response” – no cancer evident – after an average of 26.3 months.
“These findings demonstrate the potential of dostarlimab-gxly as a novel approach to treating locally advanced dMMR rectal cancer that leads to durable complete tumor regression without the need for life-altering treatment,” said Dr Andrea Cercek, researcher and oncologist at the Memorial Sloan Kettering Cancer Center (MSK). “As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these patients.”
Making Humanity A Multi-Planetary Species — Dr. Eliah Overbey, Ph.D. — Assistant Professor, Bioastronautics, University of Austin; CSO, BioAstra.
Dr. Eliah Overbey, Ph.D. is Assistant Professor of Bioastronautics at The University of Austin (UATX — https://www.uaustin.org/people/eliah–…) where she is involved in pioneering research in the field of astronaut health, specializing in spaceflight-induced genomic changes. Her work focuses on mapping changes in the human body during spaceflight and developing Earth-independent laboratories to make humans a multi-planetary species (https://www.eliahoverbey.com/).
GCC19CART has previously been evaluated in an investigator-initiated clinical trial (ChiCTR2000040645) in China for the treatment of relapsed/refractory metastatic colorectal cancer (r/r mCRC).2 Data from that trial showing improvements over standard of care (SOC) third-line therapies were presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14–19, 2023, in Orlando, Florida. Among the 21 patients included in the efficacy analysis, superior results were observed in patients (n=8) who received the higher dose level (2×106 CAR-T cells/kg; DL2) than in patients (n=13) who received the lower dose level (1×106 CAR-T cells/kg; DL1). The objective response rate was 50% (n=4) for DL2, 15% (n=2) for DL1, and 29% (n=6) for all patients.
“The new AE specific to this product is diarrhea because the target is guanylate cyclase 2C (GCC), which plays a role in intestinal homeostasis… So, that’s expected, theoretically,” Victor Lu, PhD, the chief technology officer of Innovative Cellular Therapeutics, who presented the data, said during his presentation.2 “Most patients treated with this product experienced diarrhea, but it can be controlled and because of the diarrhea management most of the patients actually recovered very quickly.”
GCC19CART targets both GCC and CD19.1 It was designed using ICT’s CoupledCAR platform, which combines 2 CAR T cells engineered to release cytokines that are thought to promote proliferation and infiltration.3 The platform was designed following observations that CD19-directed CAR T cells also stimulated the immune system, which could lead to increase proliferation for other CAR T cells, specifically those directed toward solid tumor antigens, like GCC.
The Elemind headband is a soft, lightweight, and flexible wearable designed to be worn throughout the night, regardless of one’s sleeping position. It can collect information using brainwaves and pairs with a smartphone, where users can find details about their sleep patterns.
Where the headband is effective is its ability to use neuromodulation to impact the brainwaves, directing them from wakeful patterns to those of deeper sleep. “Elemind works like noise-cancellation for the brain. You can switch off the world, switch off the stress, and go to sleep faster,” explained Meredith Perry, the CEO and co-founder of Elemind.
